{
    "id": "34233280-b3ad-c67b-e063-6394a90a7605",
    "indications": "Zolmitriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.\n                  \n                     Limitations of Use:\n                  \n                  \n                     Only use zolmitriptan tablets if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan tablets treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan tablets are administered to treat any subsequent attacks.\n                     Zolmitriptan tablets are not indicated for the prevention of migraine attacks.\n                     Safety and effectiveness of zolmitriptan tablets have not been established for cluster headache.",
    "contraindications": "Recommended starting dose: 1.25 mg or 2.5 mg ( 2.1 ) Maximum single dose: 5 mg ( 2.1 ) May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period ( 2.1 ) Moderate or Severe Hepatic Impairment: 1.25 mg recommended ( 2.3 , 8.6 )",
    "warningsAndPrecautions": "2.5 mg Tablets- Pink, round, biconvex, film-coated tablets with \"ZL 1\" engraved on one side and break line on other side are supplied in cartons containing 6 tablets (NDC 76420-336-06 relabeled from NDC 27241-021-68).\n \n                  \n                     5 mg Tablets- Yellow, round, biconvex, film-coated tablets with \"ZL 2\" engraved on one side and plain on other side are supplied in cartons containing 3 tablets (NDC 76420-337-03 relabeled from NDC 27241-022-38).\n \n                  Store zolmitriptan tablets at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Protect from light and moisture.",
    "adverseReactions": "Zolmitriptan tablets are contraindicated in patients with:\n                  \n                     Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or coronary artery vasospasm including Prinzmetal’s angina\n  \n   [see\n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ].\n \n  \n                     Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory  conduction pathway disorders\n  \n   [see\n                        \n                           Warnings and Precautions (5.2)\n                        \n                        ].\n \n  \n                     History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar  migraine because these patients are at a higher risk of stroke\n  \n   [see\n                        \n                           Warnings and Precautions (5.4)\n                        \n                        ].\n \n  \n                     Peripheral vascular disease (PVD)\n  \n   [see\n                        \n                           Warnings and Precautions (5.5)\n                        \n                        ].\n \n  \n                     Ischemic bowel disease\n  \n   [see\n                        \n                           Warnings and Precautions (5.5)\n                        \n                        ].\n \n  \n                     Uncontrolled hypertension\n  \n   [see\n                        \n                           Warnings and Precautions (5.8)\n                        \n                        ].\n \n  \n                     Recent use (i.e., within 24 hours) of another 5-HT\n  \n   1agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide)\n  \n   [see\n                        \n                           Drug Interactions (7.1\n                        \n                        ,\n                        \n                           7.3)\n                        \n                        ] .\n                     \n                     Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that is within 2 weeks)\n  \n   [see\n                        \n                           Drug Interactions (7.2)\n                        ,\n  \n   \n                        \n                           Clinical Pharmacology (12.3)\n                        \n                        ].\n \n  \n                     Known hypersensitivity to zolmitriptan (angioedema and anaphylaxis seen)\n  \n   [see\n                        \n                           Adverse Reactions (6.2)\n                        \n                        ].",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "ZOLMITRIPTAN",
            "code": "2FS66TH3YW"
        }
    ],
    "organization": "Asclemed USA, Inc.",
    "name": "Zolmitriptan",
    "effectiveTime": "20250502"
}